Xiamen Amoytop Biotech Co., Ltd. (SHA:688278)
52.89
+1.69 (3.30%)
Sep 30, 2026, 3:00 PM CST
Xiamen Amoytop Biotech Revenue
Xiamen Amoytop Biotech had revenue of 1.04B CNY in the quarter ending June 30, 2026, with 24.07% growth. This brings the company's revenue in the last twelve months to 4.02B, up 28.16% year-over-year. In the year 2025, Xiamen Amoytop Biotech had annual revenue of 3.70B with 31.18% growth.
Revenue (ttm)
4.02B
Revenue Growth
+28.16%
P/S Ratio
5.23
Revenue / Employee
1.10M
Employees
3,640
Market Cap
21.02B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.70B | 878.41M | 31.18% |
| Dec 31, 2024 | 2.82B | 716.84M | 34.13% |
| Dec 31, 2023 | 2.10B | 573.42M | 37.55% |
| Dec 31, 2022 | 1.53B | 394.68M | 34.86% |
| Dec 31, 2021 | 1.13B | 338.29M | 42.61% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Beijing Tiantan Biological Products | 5.65B |
| Yili Chuanning Biotechnology | 4.37B |
| Hualan Biological Engineering | 4.36B |
| Suzhou Zelgen Biopharmaceuticals | 1.64B |
| BrightGene Bio-Medical Technology | 1.36B |
| Sinocelltech Group | 1.25B |
| Evopoint Biosciences | 1.11B |
| Acrobiosystems | 950.35M |